IRCT20211203053261N1 IRCT 2022-05-28 Shahid Beheshti University of Medical Sciences Overactive bladder treatment by Intravaginal injection of botulinum toxin A Overactive bladder(OAB) treatment by Intravaginal injection of botulinum toxin A (Dysport): An effective outpatient procedure 2021-12-22 anticipated 50 Complete https://irct.ir/trial/60379 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 overactive bladder. Intervention 1: Intervention group: Intravaginal Dysport (Abobotulinum toxin A, Ipsen Biop- harmaceuticals, Pharma, Germany) injection: In this group, local anesthesia is applied on an outpatient basis; diluted lidocaine is injected in to the anterior wall of the vagina at the lithotomy position. The standard dose of Dysport (10 units per kilogram of patient's body weight ) is then diluted by injectable normal saline (1 cc per 100 units) and injected into 10 points of the anterior vaginal wall, adjacent to the bladder, by an insulin syringe (very fine 31 gauge needle). Foley catheter is not necessary at the end of procedure. Intervention 2: Control group: Intravesical Dysport (Abobotulinum toxin A, Ipsen Biop- harmaceuticals, Pharma, Germany) injection: After regional or general anesthesia, cystoscopy and bladder washing are performed at the lithotomy position . The appropriate dose of Dysport, equivalent to 10 units per kilogram of patient weight (maximum 1000 units), is diluted with injectable normal saline (1 cc per 100 units). The final solution is injected into 20 different points of detrusor muscle by a special 22 gauge bladder injection needle (BoNee ;Coloplast, Humlebaek, Denmark) through cystoscope, and Foley catheter is fixed at the end of the procedure. No - There is not a plan to make this available Justification or reason for not sharing IPD is The information will be entered as code in SPSS software and the analysis results will be published as a final report and article